辉瑞风险投资领投Cartography Biosciences 6700万美元B轮融资,推进结直肠癌TCE临床研究

Minhua笔记
Oct 03, 2025

10月2日,美国旧金山的生物技术初创公司Cartography Biosciences宣布完成6700万美元B轮融资,由辉瑞风投(Pfizer Ventures)领投,该资金将支持其主打候选药物CBI-1214进入临床试验。CBI-1214是一种新型T细胞接合剂(TCE),靶向结直肠癌(CRC)中微卫星稳定(MSS)和微卫星不稳定低(MSI-L)亚型的独有蛋白LY6G6D,旨在招募T细胞攻击肿瘤。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10